Ductal carcinoma in situ carries a higher risk of death than previously thought
Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general US population, according to a new study led by Dr. Steven Narod
2015-08-20
(Press-News.org) TORONTO, ON, August 20, 2015 - Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general U.S. population, according to a new study led by Dr. Steven Narod.
"Our work shows that DCIS has more in common with small invasive cancers than previously thought," explains Dr. Narod, a scientist with Women's College Research Institute and a professor with the Dalla Lana School of Public Health at the University of Toronto. "In these cases, we've found that there's an inherent potential for DCIS to spread to other organs."
In this sense, DCIS is, in fact, an early form of breast cancer.
"This paper effectively redefines our understanding of the early stages of breast cancer and shows that the cancerous behavior is present very early on," adds Dr. Narod. "There is a potential for chemotherapy to reduce the rates of death from DCIS but for most women the mortality rate (less than two per cent) is too low to justify toxic therapy."
The research paper, which was published today in JAMA Oncology, also describes how radiotherapy and mastectomy prevented recurrence but did not diminish breast cancer mortality rates.
In the current study, the researchers looked at data from over 100,000 American women who had been diagnosed with DCIS (a type of stage 0 breast cancer). From the data, the researchers found that:
About 1.1 per cent of women died of breast cancer within 10 years of being diagnosed with DCIS.
About 3.3 per cent of women died of breast cancer within 20 years of being diagnosed with DCIS.
Women diagnosed with DCIS before age 35 were 17 times more likely to die from breast cancer within 10 years, compared to women in the general U.S. population.
Black women had a higher risk of dying from breast cancer within 20 years of being diagnosed with DCIS, compared to white women.
Women with DCIS who subsequently developed an invasive form of cancer in the same breast were 18.1 times more likely to die of breast cancer.
The majority of women with DCIS (54.1 per cent) who died of breast cancer did not have an invasive in-breast recurrence of cancer, prior to death.
INFORMATION:
About DCIS: Approximately 600,000 women in the United States and 60,000 women in Canada are living with a history of DCIS - some have been told that this is an early cancer and others have been told that this is a precancerous condition. Women under age 40 and black women have the highest chance of dying of DCIS.
DCIS accounts for approximately 20 per cent of breast cancers detected through mammography. Some women with DCIS experience a second breast cancer event - and a small proportion ultimately die of breast cancer. Until now, the impact of various factors (including age at diagnosis, ethnicity and treatment) on mortality rates has not been studied.
Breast Cancer Mortality after a Diagnosis of Ductal Carcinoma in situ (DCIS)
Steven A Narod, Javaid Iqbal, Vasily Giannakeas, Victoria Sopik
About Women's College Hospital - For more than 100 years Women's College Hospital (WCH) has been developing revolutionary advances in healthcare. Today, WCH is a world leader in the health of women and Canada's leading, academic ambulatory hospital. A champion of health equity, WCH advocates for the health of all women from diverse cultures and backgrounds and ensures their needs are reflected in the care they receive. It focuses on delivering innovative solutions that address Canada's most pressing issues related to population health, patient experience and system costs. The WCH Institute for Health System Solutions and Virtual Care (WIHV) is developing new, scalable models of care that deliver improved outcomes for patients and sustainable solutions for the health system as a whole.
Women's College Research Institute (WCRI) is tackling some of the greatest health challenges of our time. Its scientists are conducting global research that advances the health of women and improves healthcare options for all, and are then translating those discoveries to provide much-needed improvements in healthcare worldwide.
For more information about how WCH and WCRI are transforming patient care, visit http://www.womenscollegehospital.ca and http://www.womensresearch.ca
ELSE PRESS RELEASES FROM THIS DATE:
2015-08-20
Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI). After a first early benefit assessment in February 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) now reexamined whether the drug offers an added benefit over the appropriate comparator therapy. The new benefit assessment was conducted because a ...
2015-08-20
Putnam Valley, NY. (Aug. 20, 2015) - Tendon injuries, especially those acquired while engaging in sports, are not easily healed due to the fibrous nature of tendon tissues which transmit forces from muscle to bone and protect surrounding tissues against tension and compression. Tendon injuries to wrists, knees, elbows and rotator cuffs, often from over use when playing golf or tennis, are increasingly common for both professional and amateur athletes ("weekend warriors") alike.
Previous studies in which human fetal progenitor tenocyte (hFPT) transplantation stimulated ...
2015-08-20
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
Published in the New England Journal of Medicine, the early phase II study, led by MSK Physician-in-Chief and Chief Medical Officer José Baselga, MD, PhD, looked at the effect of vemurafenib (Zelboraf®) in multiple nonmelanoma BRAFV600-mutated cancers in 122 patients from 23 ...
2015-08-20
HOUSTON - (Aug. 20, 2015) - Texans without health insurance are twice as likely to skip seeking primary and mental health care because of cost. That's one of the findings of a new survey released today by Rice University's Baker Institute for Public Policy and the Episcopal Health Foundation.
The report found that in the past year 32 percent of uninsured adult Texans said they had skipped primary care due to costs, compared with 16 percent of adults who have health insurance. When it comes to mental health care or counseling, 12 percent of uninsured Texans said they had ...
2015-08-20
NASA's CloudSat Satellite passed over Super Typhoon Atsani as it moved through the western North Pacific Ocean. CloudSat looked at the super typhoon from the side, revealing heavy rainfall in a sloping eyewall.
Typhoon Atsani strengthened into a super typhoon on August 19, 2015 at 0000 UTC. CloudSat flew over Atsani at 03:27 UTC, shortly after it became a super typhoon when maximum sustained winds were near 130 knots (150 mph). Atsani was equivalent to a category 4 strength hurricane.
CloudSat's cloud profiling radar (CPR), passed just to the west of Super Typhoon Atsani's ...
2015-08-20
In the 1930s, Irving Langmuir and his colleague Katharine Blodgett were working long days in the General Electric Company's research laboratory. Together, they discovered that by spreading molecules with volatile organic solvents on the surface of water, they could create a one-molecule-thick film and use it as an anti-reflective coating for glass. Later named Langmuir-Blodgett assembly, this thin-film fabrication technique became popular for creating molecule or nanoparticle monolayers and is commonly used until this day.
Since Langmuir-Blodgett assembly was first reported ...
2015-08-20
Reston, Va. (August 20, 2015) - A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.
"We were able to demonstrate in our research that PSMA PET imaging was more specific than MR imaging for detection of clinically significant high-grade prostate cancer lesions, and ...
2015-08-20
WASHINGTON, D.C., August 20 -- A first-of-its-kind, nationally representative study of siblings supports previously published research on unrelated individuals that links specific genotypes to educational attainment among adults in their mid-20s to early 30s. The research, published today in AERA Open, a peer-reviewed journal of the American Educational Research Association, found that, within families, an adolescent with a higher "polygenic score"--which summarizes previously identified genome-wide associations for educational attainment--than her or his sibling tended ...
2015-08-20
Summary: The ideal management strategy for primary cardiogenic shock is a matter of debate. After some early discouraging experiences, the use of extracorporeal life support for patients with cardiogenic shock is having a resurgence. A report from researchers in Padua, Italy finds that patients who have an acute onset of cardiogenic shock, for example following a heart attack, and are placed on extracorporeal life support, fare better than those who have a chronic cardiac pathology. In an accompanying editorial, Dr. Vivek Rao of the University of Toronto puts the findings ...
2015-08-20
Virginia Tech researchers have identified a biomarker in pre-diabetic individuals that could help prevent them from developing Type II diabetes.
Publishing in Clinical Epigenetics, the researchers discovered that pre-diabetic people who were considered to be insulin resistant -- unable to respond to the hormone insulin effectively -- also had altered mitochondrial DNA.
Researchers made the connection by analyzing blood samples taken from 40 participants enrolled in the diaBEAT-it program, a long-term study run by multiple researchers in the Fralin Translational Obesity ...
LAST 30 PRESS RELEASES:
[Press-News.org] Ductal carcinoma in situ carries a higher risk of death than previously thought
Women diagnosed with ductal carcinoma in situ (DCIS) are twice as likely to die from breast cancer compared to the general US population, according to a new study led by Dr. Steven Narod